Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | PDE2A | O00408 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778123 | 1.00 | LMNA (0.64) | LMNATP53HTTPDE2AADRB2 | |
| SCHEMBL16046022 | 1.00 | LMNA (0.64) | LMNATP53HTTPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL20791400 | 0.98 | LMNA (0.62) | LMNATP53HTTPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL31561539 | 0.98 | LMNA (0.62) | LMNATP53HTTPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL4933547 | 0.98 | LMNA (0.62) | LMNATP53HTTPDE2AADRB2 | |
| SCHEMBL19627773 | 0.85 | LMNA (0.61) | LMNATP53HTTPDE2AADRB2 | |
| SCHEMBL19634066 | 0.85 | LMNA (0.61) | LMNATP53HTTPDE2AADRB2 | |
| SCHEMBL20238511 | 0.85 | LMNA (0.61) | LMNATP53HTTPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL19613461 | 0.83 | LMNA (0.59) | LMNATP53HTTPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL19613457 | 0.83 | LMNA (0.59) | LMNATP53HTTPDE2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| CN-1914205-A | Pyrazolo [3, 4-b ] pyridine compounds and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | LMNA 4863/4885TP53 2492/4885HTT 4109/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | LMNA 3934/4885TP53 2751/4885HTT 4384/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | LMNA 3728/4885TP53 4606/4885HTT 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.